What is the appropriate dosing, administration schedule, and contraindications for midodrine oral solution (liquid) in patients with symptomatic orthostatic hypotension?

Midodrine Liquid Dosing and Administration

For symptomatic orthostatic hypotension, midodrine liquid should be dosed at 10 mg three times daily during daytime hours (morning, midday, and late afternoon—not after 6 PM), with doses spaced approximately 3-4 hours apart, and should only be used after non-pharmacologic measures have failed. 1

Dosing Schedule

The FDA-approved regimen is straightforward 1:

• Standard dose: 10 mg three times daily
• Timing: Shortly before or upon arising, midday, and late afternoon (never later than 6 PM or within 4 hours of bedtime)
• Interval: Approximately 4-hour intervals between doses; may be given at 3-hour intervals if needed to control symptoms, but not more frequently
• Maximum: Total daily doses >30 mg have been tolerated but are not systematically studied

Dose Adjustments

Renal impairment: Start at 2.5 mg doses and titrate cautiously, as the active metabolite desglymidodrine is renally excreted 1

Higher doses: Single 20 mg doses can be used, but 45% of patients develop severe supine hypertension at this dose 1. The 10 mg dose produces similar blood pressure increases (approximately 30 mmHg standing systolic at 1 hour) with better tolerability 2

Pharmacokinetics

Midodrine is a prodrug converted to the active metabolite desglymidodrine 1:

• Peak effect: 1-2 hours post-dose
• Duration: 2-4 hours
• Half-life: Desglymidodrine has a 3-4 hour half-life
• Bioavailability: 93%, not affected by food

Contraindications and Critical Warnings

Absolute contraindications 1:

• Severe organic heart disease
• Acute renal disease
• Urinary retention
• Pheochromocytoma
• Thyrotoxicosis
• Persistent and excessive supine hypertension

Major safety concern: Supine hypertension (BP >200 mmHg systolic) is the primary risk 1. To mitigate:

• Never dose after evening meal or <4 hours before bedtime
• Monitor supine and standing blood pressure regularly
• Discontinue if supine pressure increases excessively
• Consider sleeping with head elevated >10° 3

Clinical Context from Guidelines

The 2017 ACC/AHA/HRS guidelines give midodrine a Class IIa recommendation (reasonable to use) for both vasovagal syncope and neurogenic orthostatic hypotension 4. However, midodrine should only be initiated after non-pharmacologic strategies fail 3, 1:

First-line non-pharmacologic measures 3:

• Withdraw offending medications
• Increase fluid intake to ≥3 L daily
• Increase salt intake to 10 g daily
• Waist-high compression stockings (20-30 mmHg)
• Head-up tilt sleeping position
• Counter-pressure maneuvers

Efficacy Evidence

The strongest evidence comes from a 1997 multicenter RCT in 171 patients showing midodrine 10 mg three times daily significantly improved 5:

• Standing systolic BP (P<0.001 at all time points)
• Lightheadedness symptoms (P=0.001)
• Global symptom relief (P<0.001 by investigator, P=0.03 by patient)

A 2016 post-marketing tilt-table study confirmed clinical benefit, with midodrine extending time to syncope/near-syncope by 521 seconds compared to placebo (P=0.0131) 6.

Common Pitfalls

• Dosing too late in day: This causes nocturnal supine hypertension—the last dose must be before 6 PM 1
• Continuing without benefit: FDA labeling explicitly states midodrine should only be continued in patients reporting significant symptomatic improvement 1
• Using as first-line: Midodrine is indicated only when "lives are considerably impaired despite standard clinical care" 1
• Ignoring renal function: Failure to reduce initial dose in renal impairment increases toxicity risk 1

Side Effects

Most common adverse effects (generally mild-to-moderate) 7, 8:

• Scalp pruritus/tingling (13.5%)
• Piloerection
• Supine hypertension (8%)
• Urinary urgency/retention (4%)
• Paresthesias

Patient Selection

Best candidates 3:

• Neurogenic orthostatic hypotension with low blood pressure phenotype
• Failed non-pharmacologic measures
• No history of hypertension, heart failure, or urinary retention 4

Poor candidates:

• Hyperadrenergic symptoms or tendency to hypertension
• Significant renal impairment without dose adjustment
• Unable to comply with strict dosing schedule